Israeli-based MediWound Ltd. is making waves in the biopharmaceutical industry with its innovative, non-surgical solutions for tissue repair and regeneration. Their products are marketed globally, including in the United States and Europe. The company's breakthrough product, NexoBrid, is a biopharmaceutical designed to target dead or damaged tissue in adults with deep partial and full-thickness burns. This product is sold exclusively to burn centers and hospitals burn units. The company is also developing EscharEx, which has already completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. Another promising product in MediWound's pipeline is MW005, currently in Phase I/II clinical trials, which aims to treat low-risk basal cell carcinoma. With 20 years of experience behind them, MediWound Ltd. continues to change the game and provide cutting-edge solutions in the biopharmaceutical industry.
MediWound Ltd.'s ticker is MDWD
The company's shares trade on the NASDAQ stock exchange
They are based in Yavne, Israel
There are 51-200 employees working at MediWound Ltd.
It is https://www.mediwound.com/
MediWound Ltd. is in the Healthcare sector
MediWound Ltd. is in the Biotechnology industry
The following five companies are MediWound Ltd.'s industry peers: